Boehringer Ingelheim International GmbH / Ginkgo Bioworks Holdings, Inc.

Multi-indication natural-product drug discovery (Platform - synthetic biology/metagenomics)

$27.0B Global drug discovery services/technologies market 2023 (USD MM) · 405 Total deal size (USD MM upfront research + milestones)

Disease Overview

This deal is a multi-year discovery partnership rather than a single-indication licensing, with Boehringer Ingelheim deploying Ginkgo Bioworks' synthetic-biology and metagenomics platform against diseases of high unmet medical need. Target categories publicly discussed include oncology, immunology, fibrotic disease and CNS disorders, where natural-product-inspired chemistry (macrocycles, non-ribosomal peptides, polyketides) historically produced many of pharma's most successful scaffolds but has been de-emphasized by the industry since the mid-2000s owing to screening throughput limits. Industry analyses estimate roughly 40-60% of small-molecule drugs approved between 1981 and 2019 were natural products, derivatives, or inspired by natural products (Newman and Cragg 2020, J. Nat. Prod.), underscoring that the chemistry space remains under-mined. Ginkgo's metagenomic library contains DNA encoding secondary metabolite biosynthetic gene clusters from >600,000 bacterial strains, allowing heterologous expression and high-throughput phenotypic screening in yeast and bacterial chassis. Indication-level US patient counts are not applicable at the platform-deal level; disease-addressable populations will emerge only if and when specific programs advance into clinical development against named indications.

Competitive Landscape

The natural-product and synthetic-biology drug discovery landscape pits Ginkgo against a small set of platforms. Direct metagenomics / NP discovery peers: Lodo Therapeutics (acquired by Zymergen 2020, then Ginkgo 2022), Hexagon Bio (fungal biosynthetic gene clusters), Cyclica (computational, acquired by Recursion 2023), and Warp Drive Bio (legacy, merged into Revolution Medicines). Broader AI/ML + biology platforms that Boehringer could have selected include Recursion Pharmaceuticals (phenomics), Exscientia (generative chemistry, now Recursion post-merger 2024), Insitro (machine-learning biology), Relay Therapeutics (motion-based drug design, RLY-2608 PI3Kalpha program), Schrodinger (physics-based computational chemistry, SGR-1505 MALT1 program), and Isomorphic Labs (Alphabet-backed AlphaFold applications). Encapsulated-microbiome peers such as Seres Therapeutics (SER-109 / Vowst C. difficile) and Finch (shuttered 2023) sit adjacent. Big-pharma in-house synthetic-biology efforts include GSK's Open Targets and Novartis' Biomedical Research automation. Ginkgo's differentiation is scale of foundry automation and breadth of organism library; the Boehringer deal is the company's largest pharma drug-discovery partnership disclosed to date.